Laura Bergadà
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Laura Bergadà has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Llombart-Cussac
Medica Scientia Innovation Research (MedSIR), Barcelona, Spain
2 shared publications - Joan Valls
Systems Biology and Statistical Methods for Biomedical Research, IRBLleida, University of Lleida, Rovira Roure 80, 25198 Lleida, Spain
2 shared publications - Xavier Dolcet
Developmental and Oncogenic Signaling Group. Departament de Ciències Mèdiques Bàsiques/Medicina Experimental, Universitat de Lleida. Institut de Recerca Biomèdica de Lleida, IRBLleida, Lleida, Spain
2 shared publications - Anabel Sorolla
Research Group of Cancer Biomarkers, Biomedical Research Institute of Lleida (IRBLleida), 25198 Lleida, Spain
1 shared publication - Andree Yeramian
Department of Pathology and Molecular Genetics HUAV, Dept de Ciències Mèdiques Bàsiques, Institut de Recerca Biomedica de Lleida, Univeristy of Lleida, IRBLleida, Avenida Rovira Roure, No. 80, 25198, Lleida, Spain.
1 shared publication - Andrée Yeramian
Pathology Group, Department of Pathology and Molecular Genetics, Hospital Universitari Arnau de Vilanova, University of Lleida, IRB-Lleida, 80 Avinguda Alcalde Rovira Roure, 25198 Lleida, Spain
1 shared publication
Latest Publications
- 24 November 2015
- Published by Springer Nature in Molecular Imaging and Biology
- Vol. 18 (4) , 545-556
Bioluminescence Imaging to Monitor the Effects of the Hsp90 Inhibitor NVP-AUY922 on NF-κB Pathway in Endometrial Cancer
Purpose In this study, we first aimed to evaluate the effects in vitro and in vivo, of the Hsp90 inhibitor NVP-AUY922, in endometrial cancer (EC). We also aimed to track nuclear factor kappa B (NF-κB) signalling, a key pathway involved in endometrial carcinogenesis and to check whether NVP-AUY922 treatment modulates it both in vitro and in vivo. Procedures I n vitro effects of NVP-AUY922 on EC cell growth and the signalling pathways were assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), clonogenic assays, Western Blot and luciferase assay. NVP-AUY922 effect on Ishikawa (IK) xenograft growth was evaluated in vivo, and NF-κB activity was monitored using bioluminescence imaging. Results NVP-AUY922 inhibited the growth of three endometrial cell lines tested in vitro. In vivo, NVP-AUY922 reduced tumour growth of 47 % (p = 0.042) compared to control condition. Moreover, the bioluminescence signal of the tumours harbouring IK NF-κB-LUC cells was significantly reduced in NVP-AUY922-treated animals compared to untreated ones. Conclusions NVP-AUY922 reduced EC tumour growth and NF-κB signalling both in vitro and in vivo. As therapeutic resistance of EC remains a challenge for oncologists nowadays, we think that NVP-AUY922 represents a valid alternative to conventional chemotherapy, and we believe that this approach for assessing and tracking the activation of NF-κB pathway may be of therapeutic benefit.
- 24 November 2015
- Published by Springer Nature in Molecular Imaging and Biology
- Vol. 18 (4) , 545-556
Bioluminescence Imaging to Monitor the Effects of the Hsp90 Inhibitor NVP-AUY922 on NF-κB Pathway in Endometrial Cancer
Purpose In this study, we first aimed to evaluate the effects in vitro and in vivo, of the Hsp90 inhibitor NVP-AUY922, in endometrial cancer (EC). We also aimed to track nuclear factor kappa B (NF-κB) signalling, a key pathway involved in endometrial carcinogenesis and to check whether NVP-AUY922 treatment modulates it both in vitro and in vivo. Procedures I n vitro effects of NVP-AUY922 on EC cell growth and the signalling pathways were assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), clonogenic assays, Western Blot and luciferase assay. NVP-AUY922 effect on Ishikawa (IK) xenograft growth was evaluated in vivo, and NF-κB activity was monitored using bioluminescence imaging. Results NVP-AUY922 inhibited the growth of three endometrial cell lines tested in vitro. In vivo, NVP-AUY922 reduced tumour growth of 47 % (p = 0.042) compared to control condition. Moreover, the bioluminescence signal of the tumours harbouring IK NF-κB-LUC cells was significantly reduced in NVP-AUY922-treated animals compared to untreated ones. Conclusions NVP-AUY922 reduced EC tumour growth and NF-κB signalling both in vitro and in vivo. As therapeutic resistance of EC remains a challenge for oncologists nowadays, we think that NVP-AUY922 represents a valid alternative to conventional chemotherapy, and we believe that this approach for assessing and tracking the activation of NF-κB pathway may be of therapeutic benefit.
- Open Access
- 7 July 2012
- Published by Wiley in Molecular Oncology
- Vol. 6 (5) , 530-541
Blockade of NFκB activity by Sunitinib increases cell death in Bortezomib‐treated endometrial carcinoma cells
Sunitinib reduces cell viability, proliferation and induces apoptotic cell death. Sunitinib blocks either basal NFκB activity or induced by different ligands. NFκB pathway mediates the synergistic ...
- 7 July 2012
- Published by Wiley in Molecular Oncology
- Vol. 6 (5) , 530-541
Open AccessBlockade of NFκB activity by Sunitinib increases cell death in Bortezomib‐treated endometrial carcinoma cells
Sunitinib reduces cell viability, proliferation and induces apoptotic cell death. Sunitinib blocks either basal NFκB activity or induced by different ligands. NFκB pathway mediates the synergistic ...